Share on LinkedInShare on LinkedIn

ARTICLE · 25 JANUARY 2022

Summary Trial Under The PM(NOC) Regulations: Janssen's Invega Sustenna Patent Is Infringed

Gowling WLG
Gowling WLG
Contributor
Gowling WLG

Gowling WLG

The firm The firm’s lawyers speak English, French, Russian and Ukrainian. The firm’s client base...

View firm profile
Explore more from Gowling WLG

Since 2019, the Court has seen a steady stream of motions for summary judgement or summary trial in the context of patent infringement actions.

CanadaIntellectual Property

Since 2019, the Court has seen a steady stream of motions for summary judgement or summary trial in the context of patent infringement actions. Justice Manson's newly issued decision in Janssen v Pharmascience, 2022 FC 62 continues along the same current. However, this new decision is noteworthy as being the first summary trial decision on infringement in a pharma case under the Patented Medicines (Notice of Compliance) Regulations.

In the underlying action, Janssen asserts infringement of Canadian Patent No. 2,655,335 (the "335 Patent") against Pharmascience. The 335 Patent relates to dosing regimens of long-acting injectable paliperidone palmitate formulations for the treatment of schizophrenia and related disorders. The 335 Patent is listed on the Patent Register in respect of Janssen's INVEGA SUSTENNA®.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from